Belfast investor presentation

RNS Number : 0851D

Diaceutics PLC

17 February 2020

 

Diaceutics PLC

("Diaceutics" or the "Group")

Belfast investor presentation

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will hold a presentation for investors on Monday, 6 April 2020 in Belfast City. The presentation will be given jointly by Diaceutics and Fusion Antibodies plc, the specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.

On behalf of Diaceutics, Peter Keeling CEO, and Philip White, CFO, will give a Company update and overview. The event will take place at a venue in central Belfast and will commence with registration at 5.00pm for a 5.15pm start, followed by drinks and networking.

The format of the afternoon will be as follows:

5pm: arrival and registration

5.15pm: Welcome address

5.20pm - 5.50pm: Diaceutics presentation

5.50pm - 6.05pm: Q&A

6.10pm - 6.40pm: Fusion Antibodies presentation

6.40pm - 6.55pm: Q&A

7pm: Canapes, drinks and networking

8pm: Close

If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email [e-mail]. 

Enquiries:

Diaceutics PLC		www.diaceutics.com
Peter Keeling, Chief Executive Officer		Via Walbrook PR
Philip White, Chief Financial Officer
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy			Mob: [phone]
Paul McManus			Mob: [phone]

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies.  The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes.  The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects.  The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

END

 

 

NRASFWFFLESSELE